MedTrace Logo

The Study of Apelin-APJ System on Pulmonary Hypertension Patients and Healthy Subjects

NCT01590108 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2019-04-16

No results posted yet for this study

Summary

The purpose of this study is to

* Determine blood peptide levels and investigate any tissue gradients of apelin in patients with idiopathic pulmonary arterial hypertension and healthy volunteers.
* Evaluate the effect of exogenous apelin infusion on exercise performance in healthy volunteers and patients with idiopathic pulmonary arterial hypertension.

Conditions

  • Idiopathic Pulmonary Arterial Hypertension

Interventions

DRUG

(Pyr1)apelin-13

(Pyr1)apelin-13 will be infused at 30 nanomol/min intravenously. This dose has been used in healthy volunteer and patients groups

DRUG

Saline

Saline

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Principal Investigators

  • Luke Sebastian Howard, DPhil · Imperial College NHS Trust

  • Gareth D Barnes, MBChB · Imperial College NHS trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2014-09-30
Completion
2014-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01590108 on ClinicalTrials.gov